Here, we quantified the proportion of tumor-reactive T cells across multiple cancer types, and observed that although tumor-reactive CD8+ and CD4+ T cells could be identified in most samples across cohorts, the proportion was on average remarkably low (especially for non-MM tumors). The gene discussed is CD4; the disease is neoplasm.